Gossamer Bio, Inc. Income Statement
GOSS / Health Care|9 years of annual SEC 10-K data (FY2017-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 9 fiscal years. All figures from audited SEC 10-K filings.
Gossamer Bio, Inc. reported $48M in revenue and $170M in net loss for FY2025. Revenue decreased 57.7% from FY2024 to FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 0/9 (multiple financial health concerns)
- Altman Z-Score -9.62 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $48.5M | $114.7M | $0 | $0 | - | - | - | - | - |
| SG&A Expense | $37.6M | $36.1M | $38.5M | $47.6M | $45.8M | $49.7M | $39.1M | $44.1M | $262.0K |
| R&D Expense | $174.1M | $138.5M | $135.3M | $170.9M | $170.3M | $160.9M | $143.4M | $55.3M | $891.0K |
| Operating Income | -$170.7M | -$59.9M | -$183.8M | -$218.6M | -$216.1M | -$234.0M | -$186.1M | -$149.0M | -$6.7M |
| Interest Expense | - | - | $13.5M | $13.9M | $19.4M | $12.7M | $1.9M | $12.0K | - |
| Income Tax | -$88.0K | $893.0K | $0 | $0 | - | - | $0 | $0 | $0 |
| Net Income | -$170.4M | -$56.5M | -$179.8M | -$229.4M | -$234.0M | -$243.4M | -$180.3M | -$147.0M | -$6.8M |
| EPS (Basic) | -$0.75 | -$2.71 | -$1.18 | -$2.71 | -$3.13 | -$3.55 | -$3.29 | - | - |
| EPS (Diluted) | -$0.75 | -$2.71 | -$1.18 | -$2.71 | -$3.13 | -$3.55 | -$3.29 | - | - |
| Shares Outstanding | 233.7M | 225.4M | 152.6M | 84.6M | 74.8M | 68.5M | 54.7M | 6.5M | 9.2M |
| Operating Margin | -352.2% | -52.2% | - | - | - | - | - | - | - |
| Profit Margin | -351.5% | -49.3% | - | - | - | - | - | - | - |